The University of Southampton
University of Southampton Institutional Repository

Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium

Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium
Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium

T-prolymphocytic leukemia (T-PLL) has a very poor prognosis with conventional immunochemotherapy. Incidental reports suggest that allogeneic hematopoietic stem cell transplantation (allo-HSCT) might have a role in this disease. Therefore, the purpose of the present study was to analyze the outcome of transplants for T-PLL registered with the European Group for Blood and Marrow Transplantation database and the Royal Marsden Consortium. Eligible were 41 patients with a median age of 51 (24-71) years; median time from diagnosis to treatment was 12 months, and in complete remission (CR) (11), partial remission (PR) (12), stable or progressive disease (13) and unknown in 5 patients. A total of 13 patients (31%) received reduced-intensity conditioning. Donors were HLA-identical siblings in 21 patients, matched unrelated donors in 20 patients. With a median follow-up of surviving patients of 36 months, 3-year relapse-free survival (RFS) and OS was 19% (95% CI, 6-31%) and 21% (95% CI, 7-34%), respectively. Multivariate analysis identified TBI and a short interval between diagnosis and HSCT as factors associated with favorable RFS. Three-year non relapse mortality and relapse incidence were each 41% with the majority of relapses occurring within the first year. These data indicate that allo-HSCT may provide effective disease control in selected patients with T-PLL.

Adult, Aged, Female, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Prolymphocytic, T-Cell, Male, Middle Aged, Multivariate Analysis, Remission Induction, Retrospective Studies, Treatment Outcome, Journal Article
0887-6924
972-976
Wiktor-Jedrzejczak, W.
3f40345d-42e0-4577-91ee-cbf2ecdd6362
Dearden, C.
820743d1-e8d6-4f70-8f75-31415d5f210f
de Wreede, L.
e63ec466-186d-4bc8-adc0-b05431525129
van Biezen, A.
1dae7b9a-38a1-4b43-949e-a63119e5bcef
Brinch, L.
f16a254d-c7f0-4743-926d-e642472c6e07
Leblond, V.
bb9b8ab0-c595-4732-b76e-34359bf0b281
Brune, M.
c82f97b5-8317-40de-97a2-315fdd7b5c0e
Volin, L.
abcd8fe0-cad4-4806-ba04-dc8cd8e89fc3
Kazmi, M.
b3bd9458-f7f7-41bb-a533-9acb60a7506d
Nagler, A.
f65ccdf2-8918-4c30-9211-c0516a3a2c39
Schetelig, J.
195da975-e9bc-466d-800a-6f7c65e96fd5
de Witte, T.
5e9f7243-3ef6-4330-8302-fc7f59d4e381
Dreger, P.
c2d629f9-0538-49dd-8a23-dfac013a252d
Orchard, Kim
794654ab-d6cc-488a-ac11-c9217433c7a2
EBMT Chronic Leukemia Working Party
Wiktor-Jedrzejczak, W.
3f40345d-42e0-4577-91ee-cbf2ecdd6362
Dearden, C.
820743d1-e8d6-4f70-8f75-31415d5f210f
de Wreede, L.
e63ec466-186d-4bc8-adc0-b05431525129
van Biezen, A.
1dae7b9a-38a1-4b43-949e-a63119e5bcef
Brinch, L.
f16a254d-c7f0-4743-926d-e642472c6e07
Leblond, V.
bb9b8ab0-c595-4732-b76e-34359bf0b281
Brune, M.
c82f97b5-8317-40de-97a2-315fdd7b5c0e
Volin, L.
abcd8fe0-cad4-4806-ba04-dc8cd8e89fc3
Kazmi, M.
b3bd9458-f7f7-41bb-a533-9acb60a7506d
Nagler, A.
f65ccdf2-8918-4c30-9211-c0516a3a2c39
Schetelig, J.
195da975-e9bc-466d-800a-6f7c65e96fd5
de Witte, T.
5e9f7243-3ef6-4330-8302-fc7f59d4e381
Dreger, P.
c2d629f9-0538-49dd-8a23-dfac013a252d
Orchard, Kim
794654ab-d6cc-488a-ac11-c9217433c7a2

Wiktor-Jedrzejczak, W., Dearden, C., de Wreede, L., van Biezen, A., Brinch, L., Leblond, V., Brune, M., Volin, L., Kazmi, M., Nagler, A., Schetelig, J., de Witte, T. and Dreger, P. , EBMT Chronic Leukemia Working Party (2012) Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium. Leukemia, 26 (5), 972-976. (doi:10.1038/leu.2011.304).

Record type: Article

Abstract

T-prolymphocytic leukemia (T-PLL) has a very poor prognosis with conventional immunochemotherapy. Incidental reports suggest that allogeneic hematopoietic stem cell transplantation (allo-HSCT) might have a role in this disease. Therefore, the purpose of the present study was to analyze the outcome of transplants for T-PLL registered with the European Group for Blood and Marrow Transplantation database and the Royal Marsden Consortium. Eligible were 41 patients with a median age of 51 (24-71) years; median time from diagnosis to treatment was 12 months, and in complete remission (CR) (11), partial remission (PR) (12), stable or progressive disease (13) and unknown in 5 patients. A total of 13 patients (31%) received reduced-intensity conditioning. Donors were HLA-identical siblings in 21 patients, matched unrelated donors in 20 patients. With a median follow-up of surviving patients of 36 months, 3-year relapse-free survival (RFS) and OS was 19% (95% CI, 6-31%) and 21% (95% CI, 7-34%), respectively. Multivariate analysis identified TBI and a short interval between diagnosis and HSCT as factors associated with favorable RFS. Three-year non relapse mortality and relapse incidence were each 41% with the majority of relapses occurring within the first year. These data indicate that allo-HSCT may provide effective disease control in selected patients with T-PLL.

This record has no associated files available for download.

More information

Accepted/In Press date: 16 September 2011
e-pub ahead of print date: 25 November 2011
Published date: May 2012
Keywords: Adult, Aged, Female, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Prolymphocytic, T-Cell, Male, Middle Aged, Multivariate Analysis, Remission Induction, Retrospective Studies, Treatment Outcome, Journal Article

Identifiers

Local EPrints ID: 413856
URI: http://eprints.soton.ac.uk/id/eprint/413856
ISSN: 0887-6924
PURE UUID: 6da7753d-4e3d-48e2-91a2-d7db8dc28e06
ORCID for Kim Orchard: ORCID iD orcid.org/0000-0003-2276-3925

Catalogue record

Date deposited: 07 Sep 2017 16:33
Last modified: 16 Mar 2024 03:26

Export record

Altmetrics

Contributors

Author: W. Wiktor-Jedrzejczak
Author: C. Dearden
Author: L. de Wreede
Author: A. van Biezen
Author: L. Brinch
Author: V. Leblond
Author: M. Brune
Author: L. Volin
Author: M. Kazmi
Author: A. Nagler
Author: J. Schetelig
Author: T. de Witte
Author: P. Dreger
Author: Kim Orchard ORCID iD
Corporate Author: EBMT Chronic Leukemia Working Party

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×